A wide cross-section of industry players have praised the FDA’s recent draft guidance on using electronic health records (EHRs) and medical claims data in clinical trials, but they hope the agency will acknowledge issues inherent to real-world data (RWD), offer clarity in certain areas and be flexible as sponsors adjust to the new guidance.